Skip to main content
SpringerLink
Log in

Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases

  • Pediatric Rheumatology (S Ozen, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

A rational management of children and adolescents with rheumatic and autoinflammatory diseases requires the regular assessment of the level of disease activity and of child health and well-being through the use of well-validated outcome measures. Ideally, such instruments should be simple and feasible and easily applicable in standard clinical practice. In recent years, a number of novel outcome measures have been developed and validated for use in pediatric patients with rheumatic and autoinflammatory illnesses. Furthermore, there has been an increased focus on the appraisal of child and parent perception of the disease impact. The new tools have markedly enlarged the spectrum of disorders and health domains that can be assessed in a standardized way. This progress will help to enhance the reliability of research studies and clinical trials. The aim of the present review is to provide an update of the recent advances in this field of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Petty RE, Cassidy JT. Chronic arthritis in childhood. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Elsevier Saunders; 2011. p. 211–35.

    Chapter  Google Scholar 

  2. Ravelli A. Handbook of juvenile idiopathic arthritis. Adis. 2015;1–124.

  3. Federici S, Gattorno M. A practical approach to the diagnosis of autoinflammatory diseases in childhood. Best Pract Res Clin Rheumatol. 2014;28:263–76.

    Article  PubMed  Google Scholar 

  4. Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2009;23:609–24.

    Article  PubMed  Google Scholar 

  5. Luca NJ, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2014;28:331–50. A thorough review of outcome measures for pediatric rheumatic diseases, which includes the discussion of potential avenues for future research.

    Article  PubMed  Google Scholar 

  6. Filocamo G, Consolaro A, Ferrari C, Ravelli A. Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress. Clin Exp Rheumatol. 2013;31:964–8. This paper presents the rationale that underlie the development of multidimensional questionnaires for pediatric rheumatic diseases and highlights the advantages provided by the regular use of these tools in daily practice.

    PubMed  Google Scholar 

  7. Filocamo G, Consolaro A, Solari N, Palmisani E, Dalprà S, Suffia C, et al. Recent advances in quantitative assessment of juvenile idiopathic arthritis. Ann Paediatr Rheum. 2012;1:84–96.

    Article  Google Scholar 

  8. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am. 2005;52:359–72.

    Article  PubMed  Google Scholar 

  9. Brunner HI, Giannini EH. Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol. 2003;15:602–12.

    Article  PubMed  Google Scholar 

  10. Feldman BM, Grundland B, Mccullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000;27:226–33.

    CAS  PubMed  Google Scholar 

  11. Berard R, Laxer RM. Improving the quality of care in children with juvenile idiopathic arthritis: a step in the right direction. J Rheumatol. 2011;38:789–90.

    Article  PubMed  Google Scholar 

  12. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–9.

    Article  CAS  PubMed  Google Scholar 

  13. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092–102.

    Article  PubMed  Google Scholar 

  14. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–66.

    Article  PubMed  Google Scholar 

  15. Eb N, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012;71:1122–7.

    Article  Google Scholar 

  16. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2366–74. This article illustrates the process that led to the development and preliminary validation of the JADAS cutoffs corresponding to the main disease activity states in JIA.

    Article  PubMed  Google Scholar 

  17. Consolaro A, Ruperto N, Bracciolini G, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Ann Rheum Dis. 2014;73:1380–3. This article illustrates the same as above for the state of high disease activity.

    Article  PubMed  Google Scholar 

  18. Consolaro A, Calandra S, Robbiano C, Ravelli A. Treating juvenile idiopathic arthritis according to JADAS-based targets. Ann Paediatr Rheum. 2014;3:4–10.

    Google Scholar 

  19. Bulatovic CM, De Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM. Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology. 2014;53:307–12. An analysis of the metrologic properties of the JADAS, which includes the definition of its cutoffs for disease activity states.

    Article  Google Scholar 

  20. Backström M, Tynjälä P, Ylijoki H, Aalto K, Kärki J, Pohjankoski H, et al. Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study. Rheumatology (Oxford), in press.

  21. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30 Suppl 73:S157–62. This paper highlights the potential advantages of the application of the treat-to-target strategy in the management of JIA.

    PubMed  Google Scholar 

  22. Mcerlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72:1983–8.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Consolaro A, Negro G, Gallo MC, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in non-systemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703–9. This study provides a definition of the criteria for JIA activity states based on the 3-item (clinical) JADAS.

    Article  Google Scholar 

  24. Horneff G, Becker I. Definition of improvement in juvenile idiopathic arthritis using the Juvenile Arthritis Disease Activity Score. Rheumatology (Oxford). 2014;53:1229–34.

    Article  Google Scholar 

  25. Consolaro A, Ravelli A. Defining criteria for disease activity states in juvenile idiopathic arthritis. What are the optimal JADAS cut-offs? Rheumatology (Oxford), in press.

  26. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011;38:938–53.

    Article  PubMed  Google Scholar 

  27. Consolaro A, Ruperto N, Pistorio A, Lattanzi B, Solari N, Galasso R, et al. Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:1262–70.

    Article  Google Scholar 

  28. Filocamo G, Consolaro A, Schiappapietra B, Ruperto N, Pistorio N, Solari N, et al. A parent and child acceptable symptom state in juvenile idiopathic arthritis. J Rheumatol. 2012;39:856–63.

    Article  PubMed  Google Scholar 

  29. Pincus T, Mandelin AM, Swearingen CJ. Flowsheets that include MDHAQ physical function, pain, global, and RAPID3 scores, laboratory tests, and medications to monitor patients with all rheumatic diseases: an electronic database for an electronic medical record. Rheum Dis Clin North Am. 2009;35:829-xi.

    Article  Google Scholar 

  30. Consolaro A, Ruperto N, Filocamo G, Lanni S, Bracciolini G, Garrone M, et al. Seeking insights into the EPidemiology, treatment and outcome of childhood arthritis through a multinational collaborative effort: introduction of the EPOCA study. Pediatr Rheumatol Online J. 2012;10:39.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, DeWitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken). 2014;66:1775–82. This paper describes the project that led to the development and validation of the first disease activity measure for juvenile spondyloarthropathies.

    Article  Google Scholar 

  32. Lam GKW, Petri M. Assessment in systemic lupus erythematosus. Clin Exp Rheumatol. 2005;23 Suppl 39:S120–32.

    CAS  PubMed  Google Scholar 

  33. Isenberg D, Ramsey-Goldman R. Assessing patients with lupus: towards a drug responder index. Rheumatology. 1999;38:1045–9.

    Article  CAS  PubMed  Google Scholar 

  34. Gladman DD, Ginzler E, Goldsmith CH, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.

    Article  CAS  PubMed  Google Scholar 

  35. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.

    Article  CAS  PubMed  Google Scholar 

  36. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54:2989–96.

    Article  PubMed  Google Scholar 

  37. Moorthy LN, Harrison M, Peterson M, Onel K, Lehman T. Simple Measure of the Impact of Lupus Erythematosus in Youngsters (SMILEY): examination of psychometric properties [abstract]. Arthritis Rheum. 2003;48 Suppl 9:S687.

    Google Scholar 

  38. Moorthy LN, Peterson MG, Baratelli M, Harrison MJ, Onel KB, Chalom EC, et al. Multicenter validation of a new quality of life measure in pediatric lupus. Arthritis Rheum. 2007;15(57):1165–73.

    Article  Google Scholar 

  39. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum. 2003;49:7–15.

    Article  PubMed  Google Scholar 

  40. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. International myositis assessment and clinical studies group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30:603–17.

    PubMed  Google Scholar 

  41. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001;40:1262–73.

    Article  CAS  PubMed  Google Scholar 

  42. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology. 2004;43:49–54.

    Article  CAS  PubMed  Google Scholar 

  43. Ravelli A, Ruperto N, Trail L, Felici E, Sala E, Martini A. Clinical assessment in juvenile dermatomyositis. Autoimmunity. 2006;39:197–203.

    Article  PubMed  Google Scholar 

  44. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:2201–12.

    Article  PubMed  Google Scholar 

  45. Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23:665–78.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Kendall FP, McCreary EK, Provance PG. Muscles: testing and function. 4th ed. Baltimore: Williams and Wilkins; 1993.

    Google Scholar 

  47. Hicks J, Wesley R, Koziol D, Smith M, Jain M, Cintas H, et al. Preliminary validation of abbreviated manual muscle testing (MMT) in the assessment of juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum. 2000;43(Suppl):S195.

    Google Scholar 

  48. Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999;42:2213–9.

    Article  CAS  PubMed  Google Scholar 

  49. Marafon D, Consolaro A, Ferrari C, Dalprà S, Madeo A, Providenti A, et al. PReS-FINAL-2011: preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis. Pediatr Rheumatol. 2013;11 Suppl 2:24.

    Article  Google Scholar 

  50. Ferrari C, Consolaro A, Varnier GC, Rao AP, Lazarevic D, Demirkaya E, et al. Comparison of construct validity of two functional ability measures in children with juvenile dermatomyositis. Ann Rheum Dis. 2012;71 Suppl 3:427.

    Article  Google Scholar 

  51. Arkachaisri T, Vilaiyuk S, Li S, O’Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36:2819–29.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol. 2008;35:650–7.

    Article  PubMed  Google Scholar 

  53. La Torre F, Martini G, Russo R, Katsicas MM, Corona F, Calcagno G, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum. 2012;64:4143–50. A report of the project aimed to develop a disease activity score for juvenile systemic sclerosis.

    Article  PubMed  Google Scholar 

  54. Luqmani R, Bacon P, Moots R, Janssen B, Pall A, Emery P, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671.

    CAS  PubMed  Google Scholar 

  55. Luqmani R, Exley A, Kitas G, Bacon P. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol. 1997;11:423.

    Article  CAS  PubMed  Google Scholar 

  56. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827.

    Article  CAS  PubMed  Google Scholar 

  57. Demirkaya E, Ozen S, Pistorio A, Galasso R, Ravelli A, Hasija R, et al. Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S162–8. The first evaluation of the performance of disease activity measures in pediatric vasculitides.

    PubMed  Google Scholar 

  58. Dolezalova P, Price-Kuehne FE, Ozen S, Benseler SM, Cabral DA, Anton J, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis. 2013;72:1628–33. An important international collaborative study that led to devised a disease activity score for pediatric vasculitides that is suitable for use research, clinical trials, and routine practice.

    Article  PubMed  Google Scholar 

  59. Herlyn K, Hellmich B, Seo P, Merkel P. Patient reported outcome assessment in vasculitis provides important data and a unique perspective. Arthritis Care Res (Hoboken). 2010;62:1639–45.

    Article  Google Scholar 

  60. Fidanci BE, Demirkaya E, Acikel C, Fidanci K, Karaman D, Yildiz D, et al. The invisible part of the iceberg: qualitative aspects of childhood vasculitis. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S122–7. This Turkish study provides evidence-based information on physical, emotional and social aspects for the assessment of children with vasculitis.

    PubMed  Google Scholar 

  61. Exley A, Bacon P, Luqmani R, Kitas G, Gordon C, Savage C, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371–80.

    Article  CAS  PubMed  Google Scholar 

  62. Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73:2168–73. This paper paper introduces the first disease activity index for autoinflammatory diseases, including FMF, TRAPS, MKD, and CAPS.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Ozen S, Batu ED. The myths we believed in familial Mediterranean fever: what have we learned in the past years? Semin Immunopathol. 2015;37:363–9.

    Article  CAS  PubMed  Google Scholar 

  64. Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74:1636–44.

    Article  PubMed  Google Scholar 

  65. Konukbay DYD, Acikel C, Karaman D, Fidanci BE, Bilginer Y, Polat A, et al. Evaluation of biopsychosocial aspects of patients with juvenile autoinflammatory disease: a qualitative study. Ann Paediatr Rheum. 2014;3:62–71. This Turkish study is aimed to identify the domains that are worth of inclusion in a multidimensional tool for children with autoinflammatory diseases.

    Article  Google Scholar 

  66. Konukbay DYD, Acikel C, Sozeri B, Makay B, Ayaz NA, Barut K, et al. Development and validation of juvenile autoinflammatory disease multidimensional assessment report (JAIMAR). Pediatr Rheumatol. 2014;12 Suppl 1:O23.

    Article  Google Scholar 

  67. Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73:897–901. This study contains the first criteria for the assessment of treatment response in familial Mediterranean fever.

    Article  PubMed  Google Scholar 

  68. Rigante D, La Torraca I, Avallone L, Pugliese AL, Gaspari S, Stabile A. The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. Eur Rev Med Pharmacol Sci. 2006;10:173–8.

    CAS  PubMed  Google Scholar 

  69. Yesilkaya S, Acikel C, Fidanci BE, Sozeri B, Ayaz NA, Akıncı B, et al. FMF Arthritis Vasculitis and Orphan disease Research in Paediatric Rheumatology (FAVOR): developing of a new scale for assessing the adherence to colchicines treatment in pediatric patients with FMF. Pediatr Rheumatol. 2013;11 Suppl 2:194.

    Article  Google Scholar 

  70. Yesilkaya S, Acikel C, Fidanci BE, Polat A, Sozeri B, Ayaz NA, et al. Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children. Clin Exp Rheumatol. 2015;33(6 Suppl 94):156–62. This article presents a tool for the assessment of adherence to medication prescription in children with familial Mediterranean fever.

    Google Scholar 

  71. Pras E, Livneh A, Balow Jr JE, Pras E, Kastner DL, Pras M, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75:216–9.

    Article  CAS  PubMed  Google Scholar 

  72. Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35:57–64.

    Article  PubMed  Google Scholar 

  73. Kalkan G, Demirkaya E, Acikel CH, Polat A, Peru H, Karaoglu A, et al. Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one? Rheumatology (Oxford). 2012;51:743–8.

    Article  CAS  Google Scholar 

  74. Demirkaya E, Livneh A. Evaluation of the current scoring systems in familial Mediterranean fever. In Gattorno M, editor. Familial Mediterranean fever. Springer; 2015. pp.107–118.

Download references

Author information

Authors and Affiliations

  1. Gulhane Military Medical Faculty, Pediatric Rheumatology Unit, FMF Arthritis Vasculitis and Orphan Disease Research in Pediatric Rheumatology (FAVOR), 06018, Etlik, Ankara, Turkey

    Erkan Demirkaya

  2. Università degli Studi di Genova and Istituto Giannina Gaslini, via G. Gaslini 5, 16147, Genoa, Italy

    Alessandro Consolaro, Gabriella Giancane & Angelo Ravelli

  3. Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, 06100, Sıhhiye, Ankara, Turkey

    Hafize Emine Sonmez

  4. Gulhane Military Medical Faculty, School of Medicine, Division of Pediatric Rheumatology, 06018, Etlik, Ankara, Turkey

    Dogan Simsek

Authors
  1. Erkan Demirkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Consolaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hafize Emine Sonmez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gabriella Giancane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dogan Simsek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angelo Ravelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erkan Demirkaya.

Ethics declarations

Conflict of Interest

Erkan Demirkaya, Alessandro Consolaro, Hafize Emine Sonmez, Gabriella Giancane, and Dogan Simsek declare that they have no conflicts of interest. Angelo Ravelli reports personal fees from Novartis Farma, personal fees from AbbVie Pharmaceuticals, personal fees from Roche, and grants and personal fees from Pfizer, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pediatric Rheumatology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Demirkaya, E., Consolaro, A., Sonmez, H.E. et al. Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. Curr Rheumatol Rep 18, 8 (2016). https://doi.org/10.1007/s11926-015-0558-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0558-4

Keywords

Search

Navigation